Schmitz Kathryn H, Ahmed Rehana L, Hannan Peter J, Yee Douglas
Division of Clinical Epidemiology University of Pennsylvania 423 Guardian Drive, 9th floor Blockley Drive, Philadelphia, PA 19072 215-898-0901
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1672-80. doi: 10.1158/1055-9965.EPI-04-0736.
This randomized controlled trial assessed the safety and effects of twice-weekly weight training among recent breast cancer survivors. Outcomes included body size and biomarkers hypothesized to link exercise and breast cancer risk.
A convenience sample of 85 recent survivors was randomized into immediate and delayed treatment groups. The immediate group trained from months 0 to 12; the delayed treatment group served as a no exercise parallel comparison group from months 0 to 6 and trained from months 7 to 12. Measures at baseline, 6 and 12 months included body weight, height, body fat, lean mass, body fat %, and waist circumference, as well as fasting glucose, insulin, insulin resistance, insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-1, IGFBP-2, and IGFBP-3. Injury reporting was standardized.
The intervention resulted in significant increases in lean mass (0.88 versus 0.02 kg, P < 0.01), as well as significant decreases in body fat % (-1.15% versus 0.23%, P = 0.03) and IGF-II (-6.23 versus 28.28 ng/mL, P = 0.02) comparing immediate with delayed treatment from baseline to 6 months. Within-person changes experienced by delayed treatment group participants during training versus no training were similar. Only one participant experienced a study related injury that prevented continued participation.
Twice-weekly weight training is a safe exercise program for recent breast cancer survivors that may result in increased muscle mass, as well as decreased body fat % and IGF-II. The implications of these results on cancer recurrence or survival may become more evident with longer exercise intervention trials among breast cancer survivors.
这项随机对照试验评估了近期乳腺癌幸存者每周两次进行负重训练的安全性和效果。研究结果包括身体尺寸和生物标志物，这些指标被认为与运动和乳腺癌风险相关。
从85名近期幸存者中选取一个便利样本，随机分为立即治疗组和延迟治疗组。立即治疗组在第0至12个月进行训练；延迟治疗组在第0至6个月作为无运动的平行对照组，在第7至12个月进行训练。在基线、第6个月和第12个月测量的指标包括体重、身高、体脂、瘦体重、体脂百分比和腰围，以及空腹血糖、胰岛素、胰岛素抵抗、胰岛素样生长因子-I（IGF-I）、IGF-II和IGF结合蛋白-1、IGFBP-2和IGFBP-3。损伤报告采用标准化方式。
与从基线到6个月的延迟治疗相比，干预导致立即治疗组的瘦体重显著增加（0.88千克对0.02千克，P<0.01），体脂百分比显著降低（-1.15%对0.23%，P = 0.03），IGF-II显著降低（-6.23对28.28纳克/毫升，P = 0.02）。延迟治疗组参与者在训练期间与未训练期间的个体内变化相似。只有一名参与者经历了与研究相关的损伤，导致无法继续参与。
对于近期乳腺癌幸存者来说，每周两次的负重训练是一个安全的运动方案，可能会增加肌肉量，降低体脂百分比和IGF-II。随着对乳腺癌幸存者进行更长时间的运动干预试验，这些结果对癌症复发或生存的影响可能会更加明显。
